论文部分内容阅读
自1988年1月以来,我们试用小剂量三尖杉酯碱联合全反式维甲酸,双重分化诱导治疗骨髓增生异常综合征(MDS)14例。现总结报道如下。临床资料14例均为住院病人。男女各7例。平均年龄42岁(28～67岁)。诊断标准按照1982年 FAB 协作组标准,其中难治性贫血(RA)6例,原始粒细胞增多的难治性贫血(RAEB)5例,转化中的原始粒细胞增多的难治性贫血(RAEB—T)3例。方法三尖杉酯碱1mg 加入10%葡萄糖250ml 静咏滴注,每日一次,10天1疗程,休息5～7天进行下一疗程。全反式维甲酸每日60mg,分三次口服,达到完全缓解后停药。每个疗程结束后复查血象和骨髓象,三个疗程无效者可更换其它方案。疗效评定标准参照全国会议制定的急性白血病及再障疗效评定标准,将 MDS 疗效分为:完全缓解(CR)、部分缓解(PR)、进步、无效。结果 RA6例中获 CR2例、PR1例、进步1例,
Since January 1988, we have tried 14 cases of myelodysplastic syndrome (MDS) induced by dual differentiation inducing low-dose harringtonine combined with all-trans retinoic acid. Now summarized as follows. Clinical data of 14 cases were hospitalized patients. Male and female 7 cases each. The average age of 42 years (28 to 67 years old). Diagnostic criteria According to the 1982 FAB collaborative group criteria, 6 were refractory anemia (RA), 5 were refractory anemia (RAEB) with proliferative neutrophils, 5 were refractory anemia (RAEB -T) 3 cases. Methods Harringtonine 1mg 10% glucose 250ml static Wing drip once a day for 10 days a course of rest 5 to 7 days for the next course of treatment. All-trans retinoic acid daily 60mg, three times orally, to achieve complete remission after withdrawal. After each treatment review of blood and bone marrow, three courses can be replaced by other programs ineffective. Evaluation criteria with reference to the National Conference on the development of acute leukemia and aplastic anemia evaluation criteria will be divided into MDS efficacy: complete remission (CR), partial response (PR), progress and ineffective. Results RA6 cases CR2 cases, PR1 cases, 1 case of progress,